ERBB2 and gastric cancer: About 15% of breast cancers were found to be HER2+ [88] along with other solid tumors such as gastric cancer [89], and targeted therapy against HER2 proved efficacious using kinase inhibitors, monoclonal antibodies, and ADCs [90].